These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 29846705)

  • 1. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
    Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A
    Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
    Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
    Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
    Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L
    Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
    Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
    Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
    Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
    Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
    Patil V; Mahalingam K
    Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
    Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
    World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
    Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult IDH wild-type lower-grade gliomas should be further stratified.
    Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
    Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
    Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
    Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
    Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
    Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
    Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W
    J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mean apparent propagator-MRI in evaluation of glioma grade, cellular proliferation, and IDH-1 gene mutation status.
    Sun Y; Su C; Deng K; Hu X; Xue Y; Jiang R
    Eur Radiol; 2022 Jun; 32(6):3744-3754. PubMed ID: 35076759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.
    Diaz M; Jo J; Smolkin M; Ratcliffe SJ; Schiff D
    Neurology; 2021 Feb; 96(7):e1063-e1069. PubMed ID: 33361259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.